RDC 658 and Pharmaceutical Training: What ANVISA Expects and How to Comply

When ANVISA published RDC 658/2022 — Brazil’s updated regulation on Good Manufacturing Practices for pharmaceutical products — it did more than align Brazilian standards with PIC/S guidelines. It fundamentally changed how pharmaceutical companies must think about training documentation and competency verification. For training managers at pharmaceutical companies operating in Brazil, understanding what ANVISA now expects is not optional — it is the difference between a clean audit and a critical finding.

This guide covers the training-specific requirements of RDC 658, the most common gaps auditors find, and practical strategies for building a training program that holds up under inspection.

What RDC 658 Says About Training

RDC 658 replaced the earlier RDC 301/2019 and brought Brazilian GMP regulations into closer alignment with PIC/S GMP Guide PE 009-16. The training requirements are spread across several sections, but the key provisions are:

• Article 16 — All personnel must receive training in GMP principles relevant to their role, with periodic refresher training. Training must be documented.
• Article 17 — Personnel working in clean areas, with hazardous materials, or in roles where contamination or error poses a risk to product quality must receive specialized training with documented competency assessment.
• Article 18 — Training programs must be approved by the head of production or quality control (as appropriate) and records must be retained.
• Article 19 — The effectiveness of training must be periodically assessed, and records of these assessments must be available for inspection.
• Annex provisions — Specific annexes (e.g., Annex I for sterile products, Annex 13 for investigational products) add additional training requirements for specialized manufacturing contexts.

The critical shift from RDC 301 to RDC 658 is the emphasis on demonstrable competency, not just training completion. ANVISA auditors are no longer satisfied with sign-in sheets and quiz scores. They want to see evidence that employees can apply what they learned in realistic scenarios.

Common Audit Gaps in Pharmaceutical Training

Based on publicly available ANVISA inspection reports and industry analyses published by SINDUSFARMA (the Brazilian pharmaceutical industry association), the most frequently cited training deficiencies include:

1. Training Records Without Competency Evidence

Many companies document that training occurred — the instructor’s name, the date, the attendees — but cannot demonstrate that attendees achieved competency. A sign-in sheet proves attendance, not understanding. ANVISA auditors increasingly ask: “How do you know this operator can actually perform the gowning procedure correctly?“

2. Generic Training Programs

Another common finding is training that is not role-specific. RDC 658 explicitly requires that training be relevant to the individual’s responsibilities. A one-size-fits-all GMP overview does not satisfy the requirement for specialized training in Articles 16 and 17.

3. No Evidence of Effectiveness Assessment

Article 19 requires periodic assessment of training effectiveness. Many organizations conflate this with learner satisfaction surveys or end-of-course quizzes. ANVISA expects more rigorous evidence: can the employee demonstrate the behavior or knowledge in a context that resembles their actual work?

4. Outdated Training Materials

When SOPs are updated, training materials must be updated to match. Auditors frequently find training records referencing superseded SOPs, which raises questions about whether employees were trained on current procedures.

How AI Simulation Addresses These Gaps

AI-powered training simulation — where employees practice realistic scenarios by interacting with an AI that plays the role of a colleague, supervisor, or auditor — creates a fundamentally different kind of training record. Instead of documenting that someone sat in a room, you document what they said, what decisions they made, and how their performance was evaluated against specific competency criteria.

Documented Competency, Not Just Attendance

When a quality analyst practices responding to a deviation scenario in an AI simulation, the system captures the full interaction: every question asked, every explanation given, every procedural step cited. The evaluation rubric maps directly to GMP competency requirements. The result is a training record that shows what the employee knows and can do, not just that they were present.

Role-Specific Scenario Libraries

AI simulation platforms allow training managers to build scenario libraries tailored to specific roles. An operator on a sterile filling line practices different scenarios than a quality control chemist or a warehouse supervisor. Each scenario can be tagged to specific SOP references, ensuring traceability between training content and current documentation.

Realistic Effectiveness Assessment

Because AI simulations place employees in scenarios that mirror real work situations, they function as both training and assessment simultaneously. An employee who practices handling a media fill failure is demonstrating competency in real-time. The evaluation data — captured automatically — serves as the effectiveness assessment evidence that Article 19 requires.

Automatic Version Control

Well-designed simulation platforms link scenarios to specific SOP versions. When a procedure is updated, the corresponding training scenarios are flagged for review and update, creating an auditable chain of currency.

Building an RDC 658-Compliant Training Program

Here is a practical framework for pharmaceutical training managers:

Step 1: Map competency requirements to roles. Start with your organizational chart and identify, for each role, the GMP competencies required by RDC 658. Cross-reference with applicable annexes based on your manufacturing activities.

Step 2: Design scenario-based assessments. For each critical competency, create at least one simulation scenario that requires the employee to demonstrate applied knowledge. Prioritize high-risk areas: aseptic technique, deviation handling, documentation practices, and contamination prevention.

Step 3: Establish evaluation rubrics. Define what “competent” looks like for each scenario in specific, observable terms. Rubrics should reference the relevant SOP sections and RDC 658 articles. This is what auditors will review.

Step 4: Schedule and document. Implement a training calendar that includes both initial qualification and periodic reassessment. Ensure all simulation records — transcripts, scores, evaluator feedback — are stored in a system that meets ANVISA’s data integrity requirements (following ALCOA+ principles).

Step 5: Review and improve. Use aggregate training data to identify systemic knowledge gaps. If 40% of operators struggle with the same deviation scenario, that is a signal to review both the training content and the underlying SOP for clarity.

What Auditors Actually Want to See

When an ANVISA auditor reviews your training program, they are looking for a coherent narrative: the company identified what competencies each role requires, provided relevant training, assessed whether employees achieved those competencies, and has data showing continuous improvement.

AI simulation creates artifacts at every stage of that narrative. Scenario design demonstrates intentional competency mapping. Interaction transcripts demonstrate training delivery. Evaluation scores demonstrate assessment. Trend data demonstrates continuous improvement.

The companies that struggle in audits are those that treat training as a checkbox. RDC 658 makes clear that ANVISA views training as a quality system — one that should be as rigorously managed as your CAPA process or your environmental monitoring program.

Conclusion

RDC 658 is not ambiguous about what it expects: documented, role-specific, competency-verified training with periodic effectiveness assessment. The traditional combination of classroom instruction and paper sign-in sheets no longer meets this standard.

AI-powered simulation gives pharmaceutical companies a way to meet — and exceed — ANVISA’s requirements while simultaneously improving the quality of training itself. Roleplays provides pharmaceutical-grade simulation with full audit trails, role-specific scenario libraries, and evaluation data structured for regulatory review. If your next ANVISA inspection is on the horizon, learn how Roleplays can help or request a compliance-focused demo.